

SUPPLEMENTARY MATERIAL

Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial

Hitoshi Ishii¹ • Tomonori Oura² • Masakazu Takeuchi²

¹Department of Doctor-Patient Relationships, Nara Medical University, Nara, Japan

²Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan

Corresponding author: Dr Masakazu Takeuchi, Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe 651-0086, Japan; Tel: +81-78-242-9185;
e-mail: takeuchi_masakazu@lilly.com

Table S1 Treatment satisfaction and unacceptable hyperglycemia/hypoglycemia at baseline (DTSQs), week 40 (DTSQc), and week 52 (DTSQc)

	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Dulaglutide 0.75 mg
Baseline (DTSQs ^a), mean (SD)	<i>n</i> = 144	<i>n</i> = 138	<i>n</i> = 141	<i>n</i> = 144
Treatment satisfaction	23.4 (6.4)	23.6 (6.3)	23.5 (6.5)	23.9 (6.2)
Unacceptable hyperglycemia	2.9 (2.0)	3.0 (1.8)	3.0 (2.0)	2.9 (1.8)
Unacceptable hypoglycemia	0.6 (1.2)	0.4 (1.0)	0.6 (1.1)	0.5 (1.0)
Week 40 (DTSQc ^b), LSM (SE)	<i>n</i> = 142	<i>n</i> = 138	<i>n</i> = 139	<i>n</i> = 143
Treatment satisfaction	10.9 (0.5)	11.7 (0.5)	12.1 (0.5)	9.1 (0.5)
Unacceptable hyperglycemia	-1.6 (0.1)	-1.8 (0.1)	-2.0 (0.1)	-0.8 (0.1)
Unacceptable hypoglycemia	-0.8 (0.1)	-0.7 (0.1)	-1.2 (0.1)	-0.9 (0.1)
Week 52 (DTSQc ^b), LSM (SE)	<i>n</i> = 142	<i>n</i> = 134	<i>n</i> = 134	<i>n</i> = 138
Treatment satisfaction	11.5 (0.5)	12.1 (0.5)	12.3 (0.5)	8.9 (0.5)
Unacceptable hyperglycemia	-1.7 (0.1)	-1.8 (0.1)	-2.3 (0.1)	-0.6 (0.1)
Unacceptable hypoglycemia	-1.1 (0.1)	-0.9 (0.1)	-0.9 (0.1)	-0.8 (0.1)

Only patients with a non-missing baseline value and at least one non-missing postbaseline value of the response variable were included.

DTSQc Diabetes Treatment Satisfaction Questionnaire (change), DTSQs Diabetes Treatment Satisfaction Questionnaire (status), LSM least-squares mean, SD standard deviation, SE standard error.

^a The DTSQs contains 8 items, with each item assessed on a 7-point Likert scale (0 to 6). For 6 of the 8 items (Item 1 and Items 4 through 8), scores range from 0 (very dissatisfied) to 6 (very satisfied), which are summed to produce an overall treatment satisfaction score ranging from 0 to 36 (higher scores indicate greater satisfaction). Items 2 and 3 measure the perceived frequency of









unacceptable hyperglycemia and hypoglycemia, respectively, on a scale from 0 (none of the time) to 6 (most of the time).

^b The DTSQc comprises 8 items, with each item assessed on a 7-point scale ranging from -3 (much less now) to +3 (much more now).


Baseline (DTSQs)

Week 52 (DTSQc)


Tirzepatide 5 mg Tirzepatide 10 mg Tirzepatide 15 mg Dulaglutide 0.75 mg




i 7. Would you recommend this form of treatment to someone else with your kind of diabetes?




j 7. Would you recommend this form of treatment to someone else with your kind of diabetes?




k 8. How satisfied would you be to continue with your present form of treatment?




l 8. How satisfied would you be to continue with your present form of treatment?




m 2. How often have you felt that your blood sugars have been unacceptably high recently?



n 2. How often have you felt that your blood sugars have been unacceptably high recently?



o 3. How often have you felt that your blood sugars have been unacceptably low recently?



p 3. How often have you felt that your blood sugars have been unacceptably low recently?




Fig. S1 Proportion of responses at baseline (DTSQs) and week 52 (DTSQc).

The proportion of responses for each score on the 8 items of the DTSQs at baseline (**a, c, e, g, i, k, m, o**) and the DTSQc after 52 weeks of treatment with tirzepatide 5, 10, or 15 mg or dulaglutide 0.75 mg (**b, d, f, h, j, l, n, p**) for the modified intention-to-treat population (efficacy analysis set). The DTSQs comprises 8 items, with each item assessed on a 7-point Likert scale (0 to 6). Scores for 6 of the items (Item 1 and Items 4 through 8) range from 0 (very dissatisfied) to 6 (very satisfied). Items 2 and 3 measure the perceived frequency of unacceptable hyperglycemia and hypoglycemia, respectively, on a scale from 0 (none of the time) to 6 (most of the time). The DTSQc comprises 8 items, with each item assessed on a 7-point scale ranging from -3 (much less now) to +3 (much more now).

DTSQc Diabetes Treatment Satisfaction Questionnaire (change), *DTSQs* Diabetes Treatment Satisfaction Questionnaire (status).




Fig. S2: Relationship between DTSQc total score and HbA1c and body weight at week 52.

Scatterplot showing the relationship between the DTSQc total score versus change in from baseline in **(a)** HbA1c and **(b)** body weight after 52 weeks of treatment with tirzepatide 5, 10, and 15 mg and dulaglutide 0.75 mg. *P*-values are based on a test of no correlation.

DTSQc Diabetes Treatment Satisfaction Questionnaire (change), *Dula* dulaglutide, *HbA1c* glycated hemoglobin, *TZP* tirzepatide.